Case Reports in Medicine

Case Reports in Medicine / 2021 / Article

Case Report | Open Access

Volume 2021 |Article ID 5544848 |

Afdhal Afiq Abd Jalil, Sharifah Faradila Wan Muhamad Hatta, Aimi Fadilah Mohamad, Mohammed Fauzi Abdul Rani, "Denosumab as the Treatment of Recalcitrant Tuberculous Pleural Effusion-Associated Hypercalcemia", Case Reports in Medicine, vol. 2021, Article ID 5544848, 4 pages, 2021.

Denosumab as the Treatment of Recalcitrant Tuberculous Pleural Effusion-Associated Hypercalcemia

Academic Editor: Bruno Megarbane
Received08 Feb 2021
Revised22 Mar 2021
Accepted13 Apr 2021
Published20 Apr 2021


Denosumab is a human monoclonal antibody that binds to RANKL (receptor activator of nuclear factor-kappa B ligand). It has mainly been used in the treatment of osteoporosis for a variety of causes especially in situations refractory to bisphosphonates or when kidney function is impaired. It is also used in cases of malignancy-associated hypercalcemia. There are many causes of hypercalcemia, but only rarely it is associated with granulomatous diseases such as tuberculous pleural effusion. We report a case of hypercalcemia from tuberculous pleural effusion that was initially admitted with left medium abundance pleural effusion and a serum corrected calcium level of 3.48 mmol/L. The calcium level was successfully normalized within 72 hours of subcutaneous denosumab administration after other interventions have failed.

1. Introduction

Hypercalcemia has often been described in patients with granulomatous disorders, but they are rarely symptomatic [14]. Among them, pulmonary tuberculosis is the most common cause but less so among extrapulmonary cases. Locally, the incidence has been reported to be around 27.5% among patients with active tuberculosis [4], which is comparable to the incidence rate in the west or a high TB incidence country such as India [5, 6].

Acute treatment of hypercalcemia from any cause includes intravenous volume repletion or hydration, coupled with bisphosphonate, calcitonin, or denosumab, if the hypercalcemia persists despite hydration. The most suitable choice of treatment depends on the patient’s clinical condition, which includes renal function status.

Denosumab is a human monoclonal antibody that inhibits the formation, function, and survival of osteoclasts and reduces bone resorption. It has been used for the treatment of hypercalcemia as an alternative to bisphosphonate, especially in patients with reduced creatinine clearance [7, 8].

We report a case of hypercalcemia secondary to extrapulmonary tuberculosis successfully treated with denosumab after other interventions have failed to reduce the calcium level.

2. Case

A 70-year-old male with a known history of type 2 diabetes mellitus, hypertension, chronic kidney disease, and ischemic heart disease presented to the emergency department with 7-day history of gradual onset of shortness of breath, reduced effort tolerance, and lethargy. On further inquiry, there was loss of appetite for a month, but he denied any accompanying weight loss, and there was also no history of fever or night sweats. He admitted to vague abdominal and back pain that lasted for a week.

At the emergency department, he looked cachexic and dehydrated but was alert to time, place, and person. He was apyrexial with a pulse rate of 88 beats per minute and blood pressure of 131/72 mmHg, but tachypnoeic with a respiratory rate of 27 breaths per minute. The oxygen saturation, however, was maintained at 98% on room air. Respiratory examination revealed left-sided stony dullness up to the midzone on percussion with reduced air entry on the same side. Cardiovascular and gastrointestinal examinations were unremarkable.

Chest radiograph confirmed the presence of a left medium abundance pleural effusion (Figure 1).

Table 1 summarizes the results of the blood investigations including hypercalcemia with a level of 3.03 mmol/L.

InvestigationResultsNormal values

Haemoglobin9.3 g/dL13–17
Total white count2.48 × 10^9/L4–10
Platelet167 × 10^9/L150–410
Sodium134 mmol/L135–145
Potassium4 mmol/L3.5–5.1
Urea14.10 mmol/L2.78–8.07
Creatinine212 μmol/L62–106
eGFR26.9 mL/min/1.73 m2>60 mL/min/1.73 m2
Magnesium1.02 mmol/L0.66–0.99
Corrected calcium3.03 mmol/L2.20–2.55
Phosphate1.33 mmol/L0.80–1.45
Total protein83.9 g/L64.0–83.0
Albumin30 g/L35–52
Total bilirubin20 μmol/L<21
Alanine transaminase8 U/L<41
Alkaline phosphate146 U/L40–130
Gamma-glutamyl transferase (GGT)67 U/L<60
Erythrocyte sedimentation rate (ESR)>1201–15
Full blood pictureMacrocytic anemia: macrocytosis of RBC with polychromatic cells and mild rouleaux formation. No blast or abnormal lymphoid/plasmacytoid looking cell.

He was initially admitted to the ward for treatment with intravenous Augmentin and 0.9% saline hydration for presumed acute-on-chronic kidney injury as we did not have any baseline kidney function, but unfortunately his breathing deteriorated rapidly a day after admission. He became more tachypnoeic, and the arterial blood gases showed type 2 respiratory failure (pH, 7.32; pO2, 62 mmHg; pCO2, 50 mmHg; HCO3, 20; lactate, 3). In view of the worsening ventilation and his general medical condition, a decision was made to invasively ventilate him in the intensive care unit (ICU). In the ICU, his antibiotic was upgraded to intravenous piperacillin/tazobactam for presumed community-acquired pneumonia with pleural effusion and intravenous 0.9% saline 1000 mls over 24 hours for hydration was maintained.

Echocardiography demonstrated globally dilated severe hyperkinesia of the left ventricle and a severely impaired systolic function with a left ventricle ejection fraction of 20%. Because of this, the fluid balance was closely monitored to minimize the risk of pulmonary congestion.

His urine output remained good with an average of 100 mls/h equivalent to 1.4 mls/kg/h. Unfortunately, despite adequate hydration and a positive balance of 900 mls averaging over 3 days, his serum calcium continued to rise to 3.48 mmol/L.

Intravenous furosemide was also initiated as a forced diuresis measure, which also failed to bring the calcium down.

Further investigations for the cause of the pleural effusion included therapeutic and diagnostic left thoracocentesis, and blood tests for the cause of hypercalcemia were conducted during admission. The results are listed in Table 2.

InvestigationsResultsNormal values

Intact parathyroid hormone<0.5 pmol/L1.96–8.49
Total vitamin D/25-hydroxyvitamin D106.30 nmol/L50–125
Alpha fetoprotein (AFP)<1.00 ng/mL0.89–8.78
CEA1.37 ng/mL0.00–5.00
Prostate-specific antigen0.163 ng/mL0.00–4.0
Immunoglobulin A (IgA)4.3 g/L0.70–4.00
Immunoglobulin G (IgG)26.3 g/L7.0–16.0
Immunoglobulin M (IgM)1.58 g/L0.40–2.30
Kappa free light chain352.0 mg/L6.7–22.4
Lambda free light chain493.0 mg/L8.3–27.0
Kappa/lambda ratio0.710.31–1.56
Serum protein electrophoresisNo paraprotein band
Urine protein electrophoresisNo paraprotein band
Pleural fluid analysisColourStraw coloured
LDH (pleural fluid/serum)Exudative
Total protein (pleural fluid/serum)Exudative

To reduce the calcium, we decided to try him on subcutaneous denosumab at the dose of 120 mg, and his serum corrected calcium gradually improved to 2.40 mmol/L, as depicted in Table 3, after 4 days with no further drop in calcium thereafter.

Day (postdenosumab)12345678

Corrected calcium level (mmol/L)3.443.433.282.462.972.402.522.43
Serum creatinine level (μmol/L)353360370273332234345431

At day 5, the pleural fluid analysis for rapid mycobacterium liquid culture and sensitivity test came back positive for Mycobacterium tuberculosis complex. The treatment for tuberculous pleural effusion with isoniazid, rifampicin, pyrazinamide, ethambutol, and pyridoxine (2HRZ/4HR) was subsequently commenced.

He was successfully extubated after 10 days in the ICU and was transferred to the general medical ward for further management. Unfortunately, he developed a severe concomitant hospital-acquired pneumonia complicated by respiratory failure that eventually led to multiorgan failure, cardiorespiratory arrest, and death.

3. Discussion

Hypercalcemia can rarely be a manifestation of granulomatous disease including pulmonary tuberculosis [3], even rarer in tuberculous pleural effusion as in our case.

Evaluation of hypercalcemia in our patient was suggestive of a parathyroid-independent mechanism of hypercalcemia with elevated level of vitamin D. In normal situations, vitamin D3 is absorbed by the skin from ultraviolet B light which is then metabolised into 25(OH)D3 in the liver by 25-hydroxylase. 25(OH)D3 is then catalysed via 1-α-hydroxylase to an active form known as 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) which aids in calcium absorption in the gut [9].

Tuberculosis patients experience dysregulated extrarenal production of 1,25(OH)2D3 by activated alveolar macrophages which leads to increased calcium absorption in the gut and thus hypercalcemia [10]. Overproduction of 1,25(OH)2D3 is a protective mechanism against oxidative injuries due to the nitric oxide burst from granulomatous macrophages [11]. Unfortunately, in some individuals, this protective mechanism has led to a different complication. However, not everyone who suffers from TB would develop hypercalcemia as 1,25(OH)2D3 is usually produced in small quantities locally and is not brought to target sites for the regulation of calcium homeostasis. This mechanism has been associated with hypercalcemia in pulmonary TB; however, the underlying cause for hypercalcemia in tuberculous pleural effusion, as seen in our patient, remains uncertain.

A theory has been proposed that hypercalcemia in tuberculous pleural effusion could be secondary to circulating monocytes, which act as a source of 1-α-hydroxylase that could convert 25(OH)D3 to 1,25(OH)2D3. This 1,25(OH)2D3 produced by monocytes acts locally and when carried to target tissues, it may play a role in calcium homeostasis, unlike alveolar immune cells which only acts locally [12].

The management of hypercalcemia depends on the level of serum calcium, clinical symptoms, and the underlying disorder. The treatment would always start with adequate hydration and forced diuresis with furosemide followed by bisphosphonates if both measures have failed [13]. Haemodialysis may be required in the event of renal failure and corticosteroids in patients with sarcoidosis or certain neoplasms [14].

In our patient, bisphosphonate was not chosen as the first-line treatment because of the persistently low creatinine clearance (CrCl) of <30 mls/min with a serum creatinine of 212 μmol/L and the worry of further deterioration in renal function. Palmer et al. showed that a quarter of patients with baseline renal dysfunction experienced all-grade serum creatinine elevation when the hypercalcemia was treated with intravenous bisphosphonates. The incidence of serum creatinine elevation was statistically higher in those with a CrCl of <30 mL/min compared to those with CrCl ≥30 mL/min [15]. Calcitonin was also not available at our hospital, hence the decision to use denosumab.

Denosumab is a novel, fully human monoclonal antibody which prevents the receptor activator of nuclear factor-kappa B ligand from binding to its receptor and inhibits osteoclast development, activation, and survival. It has no dose adjustments for renal impairment and has a lower incidence of renal failure and acute phase reactions. It has been approved for the treatment of osteoporosis in postmenopausal women and prevention of skeletal-related events including fractures, spinal cord compression, bone pain requiring surgery/radiation therapy, and hypercalcemia in malignancy [16].

To the best of our knowledge, our case report is the second to report improvement in hypercalcemia secondary to tuberculosis with denosumab. The first case by Torres-Ortiz et al. reported normalization of serum calcium level at 48 hours postadministration and as the patient survived, they were able to observe hypocalcemia at day 16 post-administration of denosumab [17] which is a known side effect of the drug [18]. When compared with zoledronic acid treatment for patients with advanced cancer with bone metastases or myeloma, 5.7% of patients who received denosumab required intravenous calcium infusion compared to 2.7% in the zoledronic acid arm [19]. We were not able to determine if this side effect had occurred in our patient.

During our investigation, ionized calcium could have been done to confirm true hypercalcemia but the presence of two samples of elevated serum total calcium was used instead to indicate true hypercalcemia in our patient.

In conclusion, denosumab is an option for the treatment of refractory hypercalcemia in the setting of low creatinine clearance; however, careful monitoring of calcium levels post-therapy is essential after administration especially in those deficient in vitamin D.

Data Availability

The clinical data used to support the findings of this study are included within the article.

Conflicts of Interest

All authors declare no conflicts of interest.


  1. S. Thosani and M. I. Hu, “Denosumab: a new agent in the management of hypercalcemia of malignancy,” Future Oncology, vol. 11, no. 21, pp. 2865–2871, 2015. View at: Publisher Site | Google Scholar
  2. M. J. Kavanaugh, M. F. Bavaro, R. V. Barthel, R. C. Maves, and H. L. Groff, “Severe hypercalcemia as the presenting sign of tuberculosis,” Journal of Medical Cases, vol. 6, no. 8, pp. 382–384, 2015. View at: Publisher Site | Google Scholar
  3. A. Rajendra, A. Mishra, N. Francis, and R. B. Carey, “Severe hypercalcemia in a patient with pulmonary tuberculosis,” Journal of Family Medicine and Primary Care, vol. 5, no. 2, p. 509, 2016. View at: Publisher Site | Google Scholar
  4. C. K. Liam, K. H. Lim, P. Srinivas, and P. J. Poi, “Hypercalcaemia in patients with newly diagnosed tuberculosis in Malaysia,” The International Journal of Tuberculosis and Lung Disease: The Official Journal of the International Union Against Tuberculosis and Lung Disease, vol. 2, no. 10, pp. 818–823, 1998. View at: Google Scholar
  5. A. A. Abbasi, “Hypercalcemia in active pulmonary tuberculosis,” Annals of Internal Medicine, vol. 90, no. 3, pp. 324–328, 1979. View at: Publisher Site | Google Scholar
  6. T. Y. Chan, C. H. Chan, and C. C. Shek, “The prevalence of hypercalcaemia in pulmonary and miliary tuberculosis—a longitudinal study,” Singapore Medical Journal, vol. 35, no. 6, pp. 613–615, 1994. View at: Google Scholar
  7. M. I. Hu, I. G. Glezerman, S. Leboulleux et al., “Denosumab for treatment of hypercalcemia of malignancy,” The Journal of Clinical Endocrinology & Metabolism, vol. 99, no. 9, pp. 3144–3152, 2014. View at: Publisher Site | Google Scholar
  8. A. C. Dalkin and M. H. Rosner, “Denosumab in the treatment of hypercalcemia secondary to malignancy,” Orphan Drugs: Research and Reviews, vol. 5, pp. 113–121, 2015. View at: Google Scholar
  9. P. J. Tebben, R. J. Singh, and R. Kumar, “Vitamin D-mediated hypercalcemia: mechanisms, diagnosis, and treatment,” Endocrine Reviews, vol. 37, no. 5, pp. 521–547, 2016. View at: Publisher Site | Google Scholar
  10. J. Cadranel, M. Garabedian, B. Milleron, H. Guillozo, G. Akoun, and A. J. Hance, “1,25(OH)2D2 production by T lymphocytes and alveolar macrophages recovered by lavage from normocalcemic patients with tuberculosis,” Journal of Clinical Investigation, vol. 85, no. 5, pp. 1588–1593, 1990. View at: Publisher Site | Google Scholar
  11. J.-M. Chang, M.-C. Kuo, H.-T. Kuo et al., “1-α,25-Dihydroxyvitamin D3 regulates inducible nitric oxide synthase messenger RNA expression and nitric oxide release in macrophage-like RAW 264.7 cells,” Journal of Laboratory and Clinical Medicine, vol. 143, no. 1, pp. 14–22, 2004. View at: Publisher Site | Google Scholar
  12. R. Parkash, S. Dabla, N. Saini, and K. Bala, “Hyperuricaemia, hypoparathyroidism and acute hypercalcaemia: unusual complications in extrapulmonary tuberculosis,” Journal of Clinical & Diagnostic Research, vol. 13, no. 9, 2019. View at: Publisher Site | Google Scholar
  13. M. Waller, S. Murphy, N. Krishnaraj, and G. Antunes, “Respiratory failure and symptomatic hypercalcaemia complicating pulmonary tuberculosis,” Case Reports, Article ID bcr1020081081, 2009. View at: Publisher Site | Google Scholar
  14. R. Bartl and C. Bartl, “The patient with “hypercalcaemia,” Bone Disorders, Springer, Cham, Switzerland, 2017. View at: Publisher Site | Google Scholar
  15. S. Palmer, F. Tillman, P. Sharma et al., “Safety of intravenous bisphosphonates for the treatment of hypercalcemia in patients with preexisting renal dysfunction,” Annals of Pharmacotherapy, vol. 55, no. 3, pp. 303–310, 2020. View at: Publisher Site | Google Scholar
  16. E. Tsourdi, T. D. Rachner, M. Rauner, C. Hamann, and L. C. Hofbauer, “Denosumab for bone diseases: translating bone biology into targeted therapy,” European Journal of Endocrinology, vol. 165, no. 6, pp. 833–840, 2011. View at: Publisher Site | Google Scholar
  17. A. Torres-Ortiz, P. Acharya, and W. Cheungpasitporn, “Successful treatment of tuberculosis-associated hypercacemia with denosumab in a patient with acute kidney injury’,” Therapeutic Apheresis and Dialysis, vol. 23, no. 5, pp. 484-485, 2019. View at: Google Scholar
  18. B. B. McCormick, J. Davis, and K. D. Burns, “Severe hypocalcemia following denosumab injection in a hemodialysis patient,” American Journal of Kidney Diseases, vol. 60, no. 4, pp. 626–628, 2012. View at: Publisher Site | Google Scholar
  19. S. A. Boikos and H.-J. Hammers, “Denosumab for the treatment of bisphosphonate-refractory hypercalcemia,” Journal of Clinical Oncology, vol. 30, no. 29, p. e299, 2012. View at: Publisher Site | Google Scholar

Copyright © 2021 Afdhal Afiq Abd Jalil et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Related articles

No related content is available yet for this article.
 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

No related content is available yet for this article.

Article of the Year Award: Outstanding research contributions of 2021, as selected by our Chief Editors. Read the winning articles.